Clinical trials: Acute Treatment of Migraine
Migraine, Migraine With Aura
Gepant treAtments: EffectIveNess and tolERability (GAINER)
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Trial name
- GAINER (NCT05903027)
- Testing
- Rimegepant 75 MG Disintegrating Oral Tablet
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Florence
Migraine Disorders
Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.
- Trial name
- NCT00883051
- Testing
- Lasmiditan
- Where
- 39 sites in Belgium, Finland and 3 more
- Volunteers
- 512 people
- Sponsor
- Eli Lilly and Company
Acute Headache, Migraine
High- vs Standard-Dose Intravenous Magnesium for Acute Headache
Headache is one of the most common reasons for consultation in emergency departments and represents a significant cause of disability, particularly in patients with migraine and other primary headache disorders.
- Conditions
- Acute Headache, Migraine, Tension-type Headache, Cluster Headache
- Trial name
- MAGHEAD (NCT07779486)
- Testing
- Magnesium Sulfate 2 grams, Magnesium Sulfate 4 G, Paracetamol 1 g
- Where
- Tunisia
- Volunteers
- 300 people
- Sponsor
- University of Monastir
Migraine Headache
Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches
The purpose of this study was to evaluate the effectiveness and safety of a single oral dose of NPS 1776 in the acute treatment of migraine pain and associated symptoms.
- Trial name
- NCT00172094
- Testing
- NPS 1776 (800 mg), NPS 1776 (400 mg)
- Where
- 22 sites in United States
- Volunteers
- 189 people
- Sponsor
- Shire
Headache, Migraine
Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache
Currently, paracetamol and nonsteroidal antiinflammatory drugs are widely used by emergency physicians in Turkey for the treatment of patients with Acute Migraine Attack Headache The objective of the study is compare the efficacy…
- Trial name
- NCT04372264
- Testing
- Paracetamol, Dexketoprofen, Ibuprofen
- Where
- Turkey (Türkiye)
- Volunteers
- 210 people
- Sponsor
- Pamukkale University
COVID-19, Long COVID
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and…
- Conditions
- COVID-19, Long COVID, Long Covid19, SARS CoV 2 Infection
- Trial name
- NCT05780450
- Testing
- Transcranial Direct Current Therapy (tDCS)
- Where
- 2 sites in Spain
- Volunteers
- 87 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
Migraine
Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine
Opioids are commonly used to treat migraine in North American Emergency Departments. We are comparing efficacy and adverse events of hydromorphone, an opioid, to that of prochlorperazine, a dopamine antagonist with known efficacy…
- Trial name
- NCT02389829
- Testing
- Hydromorphone, Prochlorperazine, Diphenhydramine
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Montefiore Medical Center
Post Traumatic Headache
Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)
Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH.
- Trial name
- NCT07191145
- Testing
- Eptinezumab
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Sunnybrook Health Sciences Centre
Migraine
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024.
- Trial name
- NCT06532357
- Where
- United States
- Volunteers
- 1,536 people
- Sponsor
- Pfizer
Migraine With and Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.
- Trial name
- NCT03185143
- Testing
- Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE I (NCT02828020)
- Testing
- Ubrogepant
- Where
- 90 sites in United States
- Volunteers
- 1,672 people
- Sponsor
- Allergan
Migraine
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of…
- Trial name
- NCT05399459
- Testing
- Rimegepant 25 MG, Rimegepant 75 MG
- Where
- 50 sites in Japan
- Volunteers
- 897 people
- Sponsor
- Pfizer
Episodic Migraine, Chronic Migraine
i-NEED: NEw migrainE Drugs Database
Approved by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) starting in 2018, anti-CGRP monoclonal antibodies (anti-CGRP mAbs) represent the first true revolution in the preventive treatment of…
- Conditions
- Episodic Migraine, Chronic Migraine, Medication Overuse Headache
- Trial name
- i-NEED (NCT07103694)
- Testing
- anti-CGRP monoclonal antibodies, gepants, combination of sumatriptan and naproxen
- Where
- 2 sites in Italy
- Volunteers
- 2,641 people
- Sponsor
- IRCCS San Raffaele Roma
Migraine
Efficacy and Safety of BGG492 in the Treatment of Migraine
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
- Trial name
- NCT00892203
- Testing
- BGG492, Sumatriptan
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Novartis
Migraine Disorders, Headache
The Effect of Intravenous Fluid Therapy in Acute Migraine Attacks
The study is a single-center, double-blind, randomized protocol comparison. The study will be conducted in Marmara University School of Medicine Pendik Training and Research Hospital, Department of Emergency Medicine between…
- Conditions
- Migraine Disorders, Headache, Acute Pain
- Trial name
- NCT04287140
- Testing
- Bolus fluid administration
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Marmara University
Pain, Migraine
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
- Trial name
- NCT01248468
- Testing
- Aspirin, acetaminophen and caffeine, Sumatriptan
- Where
- 20 sites in United States
- Volunteers
- 752 people
- Sponsor
- Novartis
Migraine
A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.
- Trial name
- NCT00246337
- Testing
- MK0974, Rizatriptan
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Prochlorperazine vs Metoclopramide
Migraine headaches are a common reason for patients to present to an emergency department. We are comparing two different medications to see which one is better for patients who present ot an emergency room with a migraine…
- Trial name
- NCT00364806
- Testing
- Prochlorperazine, Metoclopramide
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Montefiore Medical Center
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer